Last updated: February 25, 2026
What is the Drug Identified by NDC 00065-8595?
The National Drug Code (NDC) 00065-8595 refers to Eli Lilly’s Trulicity (dulaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for type 2 diabetes management. It is administered once weekly as a subcutaneous injection.
Market Dynamics
Epidemiology and Market Size
- Global type 2 diabetes prevalence exceeds 536 million adults, projected to reach 783 million by 2045 (IDF, 2021).
- In the U.S., approximately 37.3 million people have diabetes; roughly 90-95% have type 2.
- Market penetration for GLP-1 RAs in the U.S. reached nearly 10% of type 2 diabetics in 2022.
Competitive Landscape
- Primary competitors include Novo Nordisk’s Ozempic (semaglutide) and Rybelsus (oral semaglutide), and AstraZeneca’s Byetta (exenatide).
- Despite competition, Trulicity holds the second-largest share among GLP-1 RAs in the U.S., behind Ozempic.
Clinical Adoption
- Prescribing patterns favor weekly injections over daily alternatives, boosting Trulicity’s market share.
- Cardiovascular and renal benefits associated with GLP-1 RAs influence doctor preference and patient adherence.
Regulatory and Patent Environment
- Trulicity’s patent protection expires in late 2020s; biosimilar competition expected afterward.
- Ongoing label updates for obesity indication may expand its market.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP) for a 4.5 mg weekly dose: approximately $900–$950 per month.
- Commercial insurance typically covers a significant portion, reducing out-of-pocket costs.
Historical Price Trends
- Since launch in 2014, retail price increased approximately 3-4% annually, reflecting inflation and competitiveness.
- Price adjustments often follow new formulation approvals and label expansions.
Future Price Projections
| Year |
Estimated Monthly Price |
Assumptions |
| 2023 |
$950 |
Steady inflation rate, no large market disruptions |
| 2024 |
$970 |
Slight increase, potential early biosimilar pressure |
| 2025 |
$990 |
Continued inflation, potential entry of biosimilars affecting list price |
| 2026 |
$1,020 |
Biosimilar market entry begins to impact pricing |
| 2027 |
$1,050 |
Increased biosimilar competition, possible price stabilization or decrease |
Factors Influencing Price Changes
- Biosimilar entry expected in late-2020s, potentially reducing list prices by 15-25%.
- Payer negotiations could cap price increases; list price may be higher than net realized price.
- Market expansion into obesity indications may sustain or increase demand, affecting pricing strategies.
Market Risks and Opportunities
Risks
- Biosimilar competition could reduce Trulicity’s price and market share.
- Changes in insurance coverage policies may influence utilization.
- Patent litigation delays could extend exclusivity and maintain premium pricing.
Opportunities
- Expanded use in obesity and weight management markets.
- Continued cardiovascular benefits could drive higher adoption.
- Technological advances may facilitate patient adherence and retention.
Summary
| Aspect |
Details |
| Market Size |
Estimated >$4 billion globally, with a significant U.S. share |
| Competitive Position |
Second-largest GLP-1 RA in the U.S. after Ozempic |
| Pricing Dynamics |
Current monthly list price ~$950; gradual increases ongoing |
| Price Impact Factors |
Biosimilar entry, label expansions, payer negotiations |
Key Takeaways
- Trulicity remains a key player in the type 2 diabetes segment with stable, gradually rising prices.
- Entry of biosimilars from late-2020s will likely pressure list prices downward.
- Growth will depend on expanding approved indications and competitive dynamics.
- Pricing strategies should anticipate biosimilar market entry and evolving payer negotiations.
FAQs
1. How does Trulicity compare with competitors in terms of price?
It is similar to Ozempic's pricing, with both around $950 per month, though negotiations and rebates may alter net costs.
2. What is the outlook for biosimilar competition?
Biosimilars are expected by late 2020s, potentially reducing list prices by 15-25%.
3. How does insurance coverage influence Trulicity pricing?
Manufacturers negotiate rebates and discounts with payers, affecting out-of-pocket costs but not list prices.
4. What is the potential market size expansion from additional indications?
Label expansions into obesity management can substantially increase demand, supporting stable or increased pricing.
5. Will price increases continue at past rates?
Likely gradual, subject to market pressure from biosimilars, payer negotiations, and market saturation.
References
[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th ed.
[2] IQVIA. (2022). U.S. Diabetes Drug Market Report.
[3] FDA. (2014). Trulicity (dulaglutide) prescribing information.
[4] EvaluatePharma. (2022). Biopharma Market Intelligence Report.
[5] MarketWatch. (2023). Biologics and biosimilars pricing trends analysis.
